CG Oncology, Inc. (CGON) FY2025 10-K Annual Report
CG Oncology, Inc. (CGON) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CG Oncology, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Late-stage clinical biopharma developing cretostimogene, an oncolytic immunotherapy targeting non-muscle invasive bladder cancer (NMIBC)
- • New emphasis: BLA submission initiated Q4 2025 for high-risk BCG-unresponsive NMIBC; expanded Phase 2/3 trials including combination with gemcitabine and pembrolizumab
- • Strategic shift: Positioning cretostimogene as potential first-in-class backbone bladder-sparing therapy across multiple NMIBC risk segments amid ongoing BCG shortages
- • Key metric: Over 740 patients treated with cretostimogene in clinical trials as of Jan 30, 2026; 75.5% complete response rate in Phase 3 high-risk cohort
- • Noteworthy fact: FDA granted Fast Track and Breakthrough Therapy designations for cretostimogene in high-risk BCG-unresponsive NMIBC, accelerating regulatory pathway
Management Discussion & Analysis
- • Revenue $4.0M in 2025 vs $1.1M in 2024; $3.2M commercial/development revenue in 2025 (vs $0 in 2024)
- • Net loss $161.0M in 2025 vs $88.0M in 2024; operating costs $194.8M (2025) vs $115.8M (2024) with general & admin $73.5M vs $33.7M
- • Best performing segment: commercial/development revenue $3.2M in 2025 (new from integration of Biovire); worst: license & collaboration revenue down $0.3M to $0.8M
- • Cash, cash equivalents & marketable securities $742.2M at 12/31/25; net proceeds from public offerings and ATM sales approx. $1.1B through 2025; no buybacks/dividends; capex not detailed
- • Management expects cash sufficiency >12 months; key risks include regulatory approval timing uncertainty and ongoing R&D and commercialization expenses
Risk Factors
- • Regulatory risk from FDA on novel gene-modified virus cretostimogene may delay BLA approval; FDA may issue Complete Response Letter requiring more trials
- • Macroeconomic risk from global clinical trial delays due to geopolitical issues in foreign countries impacting patient enrollment and regulatory approvals
- • Supply chain risk from inability to demonstrate comparability between cretostimogene lots from different third-party manufacturers, possibly delaying regulatory submissions
- • Competitive risk from other pharmaceutical companies recruiting bladder cancer patients for clinical trials, limiting CG Oncology’s patient enrollment pool
- • Financial risk from high dependence on a single product candidate cretostimogene in Phase 3, increasing business risk if trials fail or are delayed
CG Oncology, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$4M
▲ +254.7% YoY
Net Income
-$161M
▼ -82.9% YoY
Operating Margin
-4722.1%
▲ +534512bp YoY
Net Margin
-3985.0%
▲ +374447bp YoY
ROE
-21.4%
▼ -939bp YoY
Total Assets
$792M
▲ +4.9% YoY
EPS (Diluted)
$-2.08
▼ -47.5% YoY
Operating Cash Flow
-$132M
▼ -68.1% YoY
Source: XBRL data from CG Oncology, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CG Oncology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.